Name | N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine |
---|---|
Synonyms |
Mutated EGFR-IN-1
AZD9291 intermediate 3 1,2,4-Benzenetriamine, N-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-N-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]- N-[2-(Dimethylamino)ethyl]-5-methoxy-N-methyl-N-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-1,2,4-benzenetriamine N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N 1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]benzene-1,2,4-triamine |
Description | Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.IC50 value:Target: Mutated EGFR inhibitorMore information can be found in Patent WO 2013014448 A1.2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer. |
---|---|
Related Catalog | |
Target |
EGFRL858R EGFRExon 19 deletion/T790M EGFRT790M |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 676.5±65.0 °C at 760 mmHg |
Molecular Formula | C25H31N7O |
Molecular Weight | 445.560 |
Flash Point | 363.0±34.3 °C |
Exact Mass | 445.259003 |
PSA | 84.47000 |
LogP | 2.17 |
Vapour Pressure | 0.0±2.1 mmHg at 25°C |
Index of Refraction | 1.635 |
Storage condition | 2-8℃ |